The 5th Annual Biomarkers Congress

February 25-26, 2010
Midland Hotel, Manchester, UK » Conference Information
» View All Events

Millipore Biopharma and biomarker services – Your Source for Quality Services

What if you had a second lab to lend a hand with research and development projects? With more than 25 years of experience performing immunoassays on both human and non-human samples, Millipore’s BioPharma and Biomarker Services is here to support your laboratory projects and outsourcing needs.

Attend the 5th Annual Biomarkers congress as our guest delegate at a discounted rate!
All Pharma and Biotechnology Companies and Academic Institutions – Normal price £650, discounted price £350
All Diagnostics, Equipment and Technology Providers – Normal price £1250, discounted price £950
To benefit from it, please contact: minh-lan_nguyen@millipore.com

About Biomarkers 2010

The 5th Annual Biomarkers Congress provides a first class educational and networking opportunity for over 175 attendees to gain knowledge and insights into the Biomarkers marketplace.

This is the opportunity to learn how you can streamline your R&D process and identify potential cost savings through successful biomarker discovery, validation and clinical development. Focus on the integration of technologies & applications to bridge the gap between Discovery, Validation and Development.

Millipore Presentation:

Title: Development of in vitro tests to limit the dangers of cytokine storm Date: 25^th February 2010 Time: 10:30 a.m. - 11 a.m. Speaker: Geoff Hale, Managing Director BioPharma Services Europe The memory of the Tegenero clinical trial disaster of 2006 continues to cast a shadow over the development of immunomodulatory drugs. The near fatal drug reactions were caused by massive cytokine release induced by triggering T lymphocytes. Tools to measure this reaction in vitro were available at the time but not applied appropriately due to limited understanding of the biological nuances of different immune interventions and lack of suitable regulatory guidance. Subsequent work has led to the refinement of analytical methods so that today we can better predict, if not completely eliminate, such risks. We will illustrate these pre-clinical studies with some examples of cytokine-releasing antibodies that have progressed successfully in subsequent clinical development.

Title: Development of in vitro tests to limit the dangers of cytokine storm
Date: 25^th February 2010
Time: 10:30 a.m. - 11 a.m.
Speaker: Geoff Hale, Managing Director BioPharma Services Europe

The memory of the Tegenero clinical trial disaster of 2006 continues to cast a shadow over the development of immunomodulatory drugs. The near fatal drug reactions were caused by massive cytokine release induced by triggering T lymphocytes. Tools to measure this reaction in vitro were available at the time but not applied appropriately due to limited understanding of the biological nuances of different immune interventions and lack of suitable regulatory guidance. Subsequent work has led to the refinement of analytical methods so that today we can better predict, if not completely eliminate, such risks. We will illustrate these pre-clinical studies with some examples of cytokine-releasing antibodies that have progressed successfully in subsequent clinical development.

For more information:

Sustainability

Sustainability is an opportunity - and a responsibility. Read more in our 2008 Sustainability Report.

Find A Location

Find the Millipore office or expert closest to you.

Contact Us

We want to hear from you. Contact a specific department below or click "Suggestions and Feedback" to send your comments.